Editorial introductions
Notice bibliographique
Résumé
Current Opinion in Allergy and Clinical Immunology was launched in 2001. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of allergy and clinical immunology are divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editors and Section Editors for this issue. EDITORS Giorgio Walter CanonicaGiorgio Walter CanonicaProf. Giorgio Walter Canonica is Professor at Humanitas University, Italy, and Director of the Personalized Medicine Clinic: Asthma and Allergy at the Humanitas Clinical Research Center, Milano, Italy. He was formerly Director of the Allergy and Respiratory Diseases Clinic, Genoa University, Italy; a GALEN Centre of Excellence. Professor Canonica first specialised in pulmonary diseases after having received his medical degree from the University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research in several European universities and institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of the Dept of Medical Specialties (University Hospital S. Martino Genoa, Italy). He is a board member of ARIA (Allergic Rhinitis and its Impact on Asthma) and GALEN (Global Allergy and Asthma European Network). Professor Canonica's research interests include examination of the molecular events and interactions between immunocompetent cells, inflammatory cells and epithelial cells in allergic inflammation and airway remodelling. He is particularly involved in new strategies in the treatment of allergic disease, including biological response modifiers, such as specific immunotherapy (with a special focus on SLIT – sublingual immunotherapy) and biologics. Professor Canonica has published extensively in international journals and acts as a referee of many immunology journals. In addition, Professor Canonica is a member of a number of societies, and recently served six years as Secretary General and President Elect of the World Allergy Organisation (WAO), and was President of WAO 2008–2009 and President of Interasma 2015–2016. He was President of SIMeR (Italian Society of Respiratory Medicine) 2000–2003 and he has been Honorary President of this same society since 2007. He was President of SIAAIC Italian Society of Allergy, Asthma and Clinical Immunology (2014–2017) and is now General Executive Director of the same society. Susan M. TarloSusan M. TarloDr Susan M. Tarlo MB BS FRCP (C) is a Professor in the Department of Medicine and in the Dalla Lana School of Public Health at the University of Toronto, Canada. She is a respiratory physician at the University Health Network, Toronto Western Hospital, Canada, and at the Gage Occupational and Environmental Health Unit and Centre of Research Excellence in Occupational Diseases of St Michael's Hospital in Toronto, Canada. Her main areas of clinical practice and research are in occupational and environmental lung diseases and allergic responses, especially occupational asthma. She initially graduated from medical school at London University, UK, and underwent postgraduate training in England for four years before going to Queen's University, Kingston, Ontario, Canada, for a year as a fellow in allergy and clinical immunology, followed by respiratory medicine residency for two years at McMaster University, Hamilton, Canada. She has been in Toronto as a staff physician at the Toronto General Hospital and then at Toronto Western Hospital as well as at the Gage Occupational and Environmental Health Unit since 1976, as well as holding academic positions at the University of Toronto since that time. SECTION EDITORS Ruby PawankarRuby PawankarProf. Ruby Pawankar, MD, PhD, FRCP (UK), FAAAAI, is currently the President of the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI), President of the Indian Academy of Allergy (IAA) and Council Member of the Collegium Internationale Allergolicum (CIA). She was President of the World Allergy Organization (WAO) in 2012 and 2013, after serving in different capacities in the WAO Board since 2001. Prof. Pawankar heads the Division of Allergy in the Department of Pediatrics at Nippon Medical School, Tokyo, Japan, and is Guest Professor at the Showa University School of Medicine in Tokyo, Japan. After graduating in medicine from the Armed Forces Medical College, Pune, India, Prof. Pawankar did her residency and post-graduation from BJ Medical College, Pune, India. Thereafter, she trained in allergy and clinical immunology at the Nippon Medical School and Juntendo University School of Medicine in Tokyo, Japan, from where she obtained her doctorate. Prof. Pawankar serves on numerous committees and boards of many academic organizations and grant reviews, is a member/fellow of organizations including the American Academy of Allergy, Asthma and Immunology, the American College of Allergy and Immunology, the European Academy of Allergy and Clinical Immunology and the Japanese Society of Allergology. She is a recipient of many academic awards, including the International Distinguished Fellow Award from the American College of Allergy, Asthma and Immunology, and the Pravasi Bharatiya Samman Award from the President of India for excellence in medicine. Prof. Pawankar's research has focused on the cellular and molecular mechanisms of allergy, immune cells like mast cells and T cells, epithelial cell-immune cell interactions, novel roles of IgE, mast cell-IgE cascade, environmental pollution, immunotherapy and novel therapies for respiratory allergies. Currently her group focuses on biomarkers in asthma and the gut microbiome in early life in relation to allergic diseases. Her research and educational activities have been strongly translational as it applies to clinical science. This has resulted in 499 publications (h-index 66) including peer-reviewed original articles, invited reviews and book chapters. She has also been an Editor/Associate Editor of several peer-reviewed journals such as International Archives of Allergy, Clinical Experimental Immunology, and Current Opinion in Allergy and Clinical Immunology, WAO J, and books including Allergy Frontiers (Springer Nature), the WAO White Book on Allergy, Update on Respiratory Disorders, Monograph on Allergies and is a co-author of several consensus documents. Prof. Pawankar has organized several international congresses as well as several educational programs and has been a visiting faculty to lecture at several institutions. David SkonerDavid SkonerDr David P. Skoner is currently the Director of the Division of Allergy and Immunology, West Virginia University Children's Hospital, USA, and Clinical Professor of Pediatrics, West Virginia University School of Medicine, USA. Previously, he served as Director of the Division of Allergy, Asthma and Immunology at Allegheny Health Network in Pittsburgh, USA, Professor of Medicine at Temple University's School of Medicine, USA, Associate Professor of Pediatrics and Otolaryngology at the University of Pittsburgh School of Medicine, USA, and Chief of the Section of Allergy/Immunology and Director of the Allergy and Immunology Training Program at the Children's Hospital of Pittsburgh, USA. He is board-certified in both pediatrics and allergy-immunology. Dr Skoner received his BS degree from Juniata College in Huntingdon, Pennsylvania, USA, and his MD degree from Temple University in Philadelphia, Pennsylvania. He served his residency in general pediatrics at Children's Hospital in Cincinnati, Ohio, USA, and completed his fellowship in Allergy/Immunology at Children's Hospital of Pittsburgh. His current research interests include the relationships between respiratory viruses, asthma, immunity, and stress; the relationship between viral and allergen-induced nasal inflammation and middle ear disease; and the efficacy and safety (HPA axis function and growth in children) of inhaled and intranasal steroids. Dr Skoner has received NIH funding, written more than 250 articles, and given more than 500 presentations on respiratory disease in over 60 countries on six continents. His articles and abstracts have been published in many leading journals, including Pediatrics, Journal of Allergy and Clinical Immunology, Pediatric Research, American Journal of Respiratory and Critical Care Medicine, JAMA, and American Review of Respiratory Disease. Dr Skoner serves on the editorial advisory boards of the journals Current Allergy and Asthma Reports, and Current Opinion in Allergy and Clinical Immunology, and previously served on the editorial board of the American Journal of Rhinology. He is a Fellow of the American Academy of Pediatrics and a member of the Society of Pediatric Research, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, the Association for Research in Otolaryngology, and the American Pediatric Society. He has been recognized as one of America's “Top Doctors” (Pediatric Allergy and Immunology, Castle Connolly Medical Ltd.) from 2001 to 2014, as one of the Most Influential Doctors by USA TODAY (http://www.usatoday.com/yourlife/health/most-influential-doctors.htm), and as a U.S. News Top Doctor (www.usnews.com/top-doctors). He was invited to join the Best Pharmaceuticals for Children Act (BPCA) Pediatric Asthma Therapeutics Group convened by the National Institute of Child Health and Human Development. Dr Skoner co-founded the International Asthma Conference at Nemacolin (www.asthma-nemacolin.com), a CME program that attracts an international audience and faculty, now in its nineteenth year. Dr Skoner also founded two non-profit organizations, For Your Good Health (www.fygh.org) and Maci's TEAMS (www.macisteams.org), designed to keep children with allergy and asthma “active” and “safe on medications”, respectively. These non-profits bring together asthma stakeholders in the development and implementation of state-of the-art programs to educate children with asthma and their caregivers about the disease and its management, including medication safety. The aim of these programs is to reduce asthma's impact on patients, caregivers, the community, and the healthcare system by helping the patients to lead near-normal lives and be free of medication side effects. He also previously served on the board of the non-profit Greater Pittsburgh Allergy Asthma and Immunology Society (GPAAIS), which serves to educate and inform physicians and other health care providers. Dr Skoner was selected as a finalist in the category of “Health Care Provider: Physician” for the 2013 Pittsburgh Business Times Health Care Heroes Awards. Andrew GrantAndrew GrantDr Grant is a native of Florida and received his undergraduate degree from Harvard University, USA, in biochemical sciences. After attending Duke Medical School, USA, he did a residency in internal medicine at New York Hospital – Cornell Medical Center in New York City, USA. He did a fellowship in immunology with Leroy Hood at the National Institutes of Health and an allergy-immunology clinical fellowship at Johns Hopkins University, USA, with Phillip Norman and Lawrence Lichtenstein. In 1973, he established the first basic and clinical research program in allergy in Texas at the University of Texas Medical Branch in Galveston, USA. Presently, he is Clinical Professor in the Departments of Medicine and Microbiology-Immunology and training program director in allergy-immunology at that institution. He has served as Division Director and Vice Chair for Research within the Department of Internal Medicine. He vacations during the summer months in Colorado and has been appointed Clinical Professor at University of Colorado Medical School, USA. Dr Grant has been an active member of the American Academy of Allergy, Asthma and Immunology for over four decades. His contributions to this organization include chairing the Program Directors Assembly, Mechanisms of Allergy Interest Section, Postgraduate Education Committee, Scientific Workshops and Exhibits Committee, and Immunotherapy Committee. He served on the Editorial Board of the Journal of Allergy and Clinical Immunology. He founded In-training Examination for Allergy-Immunology postdoctoral fellows, the first subspecialty exam of its type. Dr Grant served as President of the Texas Allergy Asthma and Immunology Society and a Director of the American Board of Allergy and Immunology, and a member of the Residency Review Committee for Allergy and Immunology. He chaired the Pulmonary Allergy Drugs Advisory Committee of the Food and Drugs Administration and is currently a member of the Allergenic Products Advisory Committee. He was a visiting professor at the National Heart and Lung Institute with Professor Barry Kay in 1994. Dr Grant's research interests have included mechanisms of cellular activation especially the role of chemokines and novel therapies for allergic disorders. Currently he is emphasizing management of difficult patients with urticaria and angioedema. He has authored over 190 publications and chapters and 175 presentations at national and international meetings.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,006 | 0,050 |
| Méta-épidémiologie (sens strict) | 0,003 | 0,001 |
| Méta-épidémiologie (sens large) | 0,002 | 0,002 |
| Bibliométrie | 0,005 | 0,002 |
| Études des sciences et des technologies | 0,003 | 0,001 |
| Communication savante | 0,008 | 0,005 |
| Science ouverte | 0,003 | 0,003 |
| Intégrité de la recherche | 0,006 | 0,007 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,171 | 0,109 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».